News

Antapodia Therapeutics, Inc. announces the collaboration with Curadigm (curadigm.com), an early-stage nanotechnology company, to harness its proprietary "liver-blocking" Nanoprimer technology to increase the bioavailability of AP-01, the first-in-class invadopodia-targeted LNP-siRNA therapy, in non-liver tumors and metastatic cancers. A series of proof-of-concept studies have shown a tremendous anti-tumor efficacy of the Nanoprimer/AP-01 combo therapy in primary and metastatic triple-negative breast cancers. Antapodia and Curadigm are currently exploiting this breakthrough strategy in other types of highly aggressive and pro-metastatic cancers.

Logo_vertical_light.png

Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.

Search